Kommentar der Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) zur S2k-Leitlinie Multiple Sklerose Commentary of the German multiple sclerosis therapy consensus group (MSTKG) on the S2k guideline on multiple sclerosis
Ontology highlight
ABSTRACT:
SUBMITTER: Wiendl H
PROVIDER: S-EPMC8207810 | biostudies-literature |
REPOSITORIES: biostudies-literature
Similar Datasets
Project description:Carbon monoxide (CO) can occur in numerous situations and ambient conditions, such as fire smoke, indoor fireplaces, silos containing large quantities of wood pellets, engine exhaust fumes, and when using hookahs. Symptoms of CO poisoning are nonspecific and can range from dizziness, headache, and angina pectoris to unconsciousness and death. This guideline presents the current state of knowledge and national recommendations on the diagnosis and treatment of patients with CO poisoning. The diagnosis of CO poisoning is based on clinical symptoms and proven or probable exposure to CO. Negative carboxyhemoglobin (COHb) levels should not rule out CO poisoning if the history and symptoms are consistent with this phenomenon. Reduced oxygen-carrying capacity, impairment of the cellular respiratory chain, and immunomodulatory processes may result in myocardial and central nervous tissue damage even after a reduction in COHb. If CO poisoning is suspected, 100% oxygen breathing should be immediately initiated in the prehospital setting. Clinical symptoms do not correlate with COHb elimination from the blood; therefore, COHb monitoring alone is unsuitable for treatment management. Especially in the absence of improvement despite treatment, a reevaluation for other possible differential diagnoses ought to be performed. Evidence regarding the benefit of hyperbaric oxygen therapy (HBOT) is scant and the subject of controversy due to the heterogeneity of studies. If required, HBOT should be initiated within 6 h. All patients with CO poisoning should be informed about the risk of delayed neurological sequelae (DNS).
| S-EPMC8607608 | biostudies-literature
Project description:BackgroundA total of 2.8 million people are living with multiple sclerosis and due to disparities in access to medicines, the ability to treat this condition varies widely. Off-label disease-modifying therapies are sometimes more available or affordable in different health systems. Appropriate methodology is integral in creating high-quality and trustworthy guidelines. In this article, we outline Multiple Sclerosis International Federation's (MSIF) approach to creating guidelines for off-label treatments for multiple sclerosis.MethodsWe use the Guidelines International Network (GIN)-McMaster Guideline Development Checklist and the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) Evidence-to-Decision (EtD) framework. We developed detailed health descriptors for health outcomes and the panel drafted PICO (Population, Intervention, Comparator, Outcome) questions and prioritised outcomes. We collaborate with independent organisations, which systematically review and collate the information. We are actively engaging stakeholders and consulting with relevant organisations, boards, working groups and individuals.ResultsThe draft guideline recommendations will be published for open comment and stakeholders will be encouraged to endorse and disseminate the guidelines. Our methodology ensures integrity and transparency in the criteria, evidence and judgement used to make recommendations.ConclusionsThis approach will facilitate transparent creation of high-quality and trustworthy guidelines, and allow the global guidelines to be adopted or adapted into national settings.
| S-EPMC8655455 | biostudies-literature
Project description: Not available
| S-EPMC4813053 | biostudies-literature
Project description:This guideline is aimed at registrars and consultants in dermatology, ophthalmology, ENT, pediatrics, neurology, virology as well as infectiology, anaesthesia and generell medicine as well as policymakers and payers and purchasers of care. It was developed by dermatologists, virologists, ophthalmologists, ENT physicians, neurologists, pediatrician and anesthetists using a formal consensus process (S2k).The guideline provides an overview of clinical and molecular diagnostics as well as antigen detection, antibody culture and viral culture. Diagnostic special situations and complicated courses of the disease are also considered. The antiviral therapy of zoster and postzoster neuralgia is presented in general and for special situations. Detailed information on the treatment of pain is mentioned and presented in an overview. Likewise, the local therapeutic measures are discussed.
| S-EPMC7187398 | biostudies-literature
Project description: Not available
| S-EPMC8445862 | biostudies-literature
Project description:The aim of the study was to validate a German version of the Vividness of Movement Imagery Questionnaire 2 (VMIQ-2; Roberts, Callow, Hardy, Markland, & Bringer, 2008), which measures external visual, internal visual, and kinesthetic vividness of movement imagery. The psychometric characteristics of the German version did not differ significantly from the English version. Using confirmatory factor analyses, the three-dimensional structure of the VMIQ-2 was replicated with reasonable fit and good internal consistency. The test-retest reliability was moderate. Thus, the German version of the VMIQ-2 is a valid instrument for measuring the vividness of movement imagery.
| S-EPMC7145442 | biostudies-literature
Project description:Primary objectives: To verify the superiority of a combined chemo-immuno-therapy compared to exclusive chemotherapy.
Primary endpoints: progression of tumor (new lesions or increase by more than 20% acc to RECIST criteria)
| 2519927 | ecrin-mdr-crc
Project description:Die Kommission 1.4 Anhaltszahlen und Qualitätssicherung der Deutschen Gesellschaft für Neurologie führt alle 2 Jahre eine Umfrage unter den an der Akutversorgung neurologischer Patienten teilnehmenden neurologischen Kliniken in Deutschland durch. Anhaltszahlen zur akutneurologischen Versorgung in Deutschland, der Infrastruktur der Krankenhäuser und der neurologischen Fachabteilungen aus dem Jahr 2019 wurden 2020 erfragt und mit den Ergebnissen der Vorumfragen verglichen. Bei hoher Antwortquote von 67 % gehörte zu den wesentlichen Ergebnissen, dass die Größe der Kliniken und deren Ertragsstärke seit 2015 weitgehend stagnieren. Dies korreliert zeitlich mit dem seit 2015 anhaltenden, die Versorgung einschränkenden Pflegepersonalmangel und dem im Vergleich zu 2017 leicht gemilderten Ärztemangel. Der Ärztemangel konnte durch Rekrutierung von Ärzten aus dem Ausland abgemildert werden. Mindestens einen Arzt mit einem Examen von außerhalb der Europäischen Union beschäftigten 71 % der Kliniken. Nur eine Minderheit bietet spezielle Fortbildungsangebote für aus dem Ausland rekrutierte Ärzte an. Ambulante Strukturen wurden weiter ausgebaut. Zur Thrombektomie müssen Patienten von 1/3 der Kliniken verlegt werden und mehr als 50 km Transportweg überwinden. Im Vergleich zu 2017 erfolgen zumindest zeitweise Thrombektomien in insgesamt deutlich mehr Kliniken. Allerdings führten 48 Kliniken durchschnittlich weniger als 1 Thrombektomie/Woche durch. Obwohl etwa 1/3 der Krankenhäuser, aus denen Antworten eingingen, sog. Kalkulationshäuser sind, erhielt nur die Hälfte der neurologischen Fachabteilungen an diesen Häusern differenzierte Rückmeldungen zur Kostenstruktur. Die Anhaltszahlenumfrage zum Jahr 2019 zeigt schlaglichtartig Problemfelder neurologischer Kliniken in Deutschland auf, die aktuell durch die Pandemielage überdeckt sein mögen, aber bereits jetzt als Herausforderungen für die Rückkehr zur Normalität identifiziert werden können. Zusatzmaterial online Zusätzliche Informationen sind in der Online-Version dieses Artikels (10.1007/s42451-021-00358-y) enthalten. Beitrag und Zusatzmaterial stehen Ihnen auf www.springermedizin.de zur Verfügung. Bitte geben Sie dort den Beitragstitel in die Suche ein, das Zusatzmaterial finden Sie beim Beitrag unter „Ergänzende Inhalte“.
| S-EPMC8287115 | biostudies-literature
Project description:Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, Switzerland).
| S-EPMC8300076 | biostudies-literature
Project description:Background and Purpose: Patients with severe, progressive multiple sclerosis (MS) have complex physical and psychosocial needs, typically over several years. Few treatment options are available to prevent or delay further clinical worsening in this population. The objective was to develop an evidence-based clinical practice guideline for the palliative care of patients with severe, progressive MS. Methods: This guideline was developed using the Grading of Recommendations Assessment, Development and Evaluation methodology. Formulation of the clinical questions was performed in the Patients-Intervention-Comparator-Outcome format, involving patients, carers and healthcare professionals (HPs). No uniform definition of severe MS exists: in this guideline, constant bilateral support required to walk 20?m without resting (Expanded Disability Status Scale score >6.0) or higher disability is referred to. When evidence was lacking for this population, recommendations were formulated using indirect evidence or good practice statements were devised. Results: Ten clinical questions were formulated. They encompassed general and specialist palliative care, advance care planning, discussing with HPs the patient's wish to hasten death, symptom management, multidisciplinary rehabilitation, interventions for caregivers and interventions for HPs. A total of 34 recommendations (33 weak, 1 strong) and seven good practice statements were devised. Conclusions: The provision of home-based palliative care (either general or specialist) is recommended with weak strength for patients with severe, progressive MS. Further research on the integration of palliative care and MS care is needed. Areas that currently lack evidence of efficacy in this population include advance care planning, the management of symptoms such as fatigue and mood problems, and interventions for caregivers and HPs.
| S-EPMC7583337 | biostudies-literature